<DOC>
	<DOCNO>NCT00714077</DOCNO>
	<brief_summary>The purpose study : - To compare long-term survival local/regional control two postoperative concurrent chemoradiotherapy regimen : capecitabine vs. oxaliplatin capecitabine , stage II III rectal cancer - To compare toxicity profile two different concurrent chemoradiotherapy regimen .</brief_summary>
	<brief_title>Adjuvant Treatment Concurrent RT CAPOX Capecitabine Alone Stage II III Rectal Cancer</brief_title>
	<detailed_description>Adjuvant 5-FU base concurrent chemoradiotherapy chemotherapy standard care locally advanced stage II-III rectal cancer , base several randomized Phase III clinical trial . With standard treatment , 5-year local failure rate distant metastasis rate 10 % around 35 % , respectively . Capecitabine , analog 5-fluoruracil ( 5FU ) , demonstrate similar treatment result compare 5-FU , much low toxicity . Oxaliplatin base chemotherapy , also show good disease-free survival rate compare 5-FU based-regimen . So far , Phase I/II study show safety preliminary result either concurrent chemotherapy capecitabine oxaliplatin capecitabine . The long-term result comparison capecitabine concurrent chemoradiotherapy oxaliplatin/capecitabine concurrent chemoradiotherapy need analyze .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1875 year old , male female R0 surgery Pathologically approve stage II stage III Enrolled within 6 month date surgery Upper border tumor surgery L5 KPS &gt; 70 % ECOG 02 No prior radiotherapy past 6 month Received chemotherapy 4 cycle surgery HGB &gt; 100 g/L , WBC≥3.5x109 /L , PLT≥100x109 /L ; CR &lt; 1.5 x Upper normality，TB &lt; 2.5 X Upper normality，AST ALT &lt; 2.5 x Upper normality，AKP &lt; 2.5 X Upper normality Signed consent Other malignancy simultaneously except situ cervix nonmelanoma skin cancer Pregnancy lactation HGB &lt; 100 g/L , WBC &lt; 3.5x109 /L , PLT &lt; 100x109 /L ; CR≥1.5 x Upper normality，TB≥2.5 X Upper normality，AST ALT≥2.5 x Upper normality，AKP≥2.5 X Upper normality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>concurrent chemoradiotherapy</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>phase III study</keyword>
</DOC>